Tweet
Int J Stem Cells. 2016 Nov 30;9(2):207-212. doi: 10.15283/ijsc16049.
Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.
Abi Chahine N1, Wehbe T2, Rashed J3, Hilal R4, Elias N5
Abstract
Stem cell therapy, an evolving, progressive field of therapeutics has shown several successes in areas where classic treatments failed to prevent or stop disability. Starting in 2009, twenty two sequential patients with progressive Multiple Sclerosis (MS) courses were treated with Autologous Bone Marrow Mononuclear stem cells (BM-MNSCs). The cells were given both intravenously and intrathecally. Using the Expanded Disability Status Scale (EDSS) score for evaluation, our data indicates that the majority of the patients benefited on the average one point on the scale. This paper adds to the body of evidence suggesting the safety and efficacy of autologous BM-MNSCs in the treatment of MS and awaits validation through larger, randomized studies.
STUDY IN PROCESS OF PUBLISHING
MORE: https://www.ncbi.nlm.nih.gov/pubmed/27788571
Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.
Abi Chahine N1, Wehbe T2, Rashed J3, Hilal R4, Elias N5
Abstract
Stem cell therapy, an evolving, progressive field of therapeutics has shown several successes in areas where classic treatments failed to prevent or stop disability. Starting in 2009, twenty two sequential patients with progressive Multiple Sclerosis (MS) courses were treated with Autologous Bone Marrow Mononuclear stem cells (BM-MNSCs). The cells were given both intravenously and intrathecally. Using the Expanded Disability Status Scale (EDSS) score for evaluation, our data indicates that the majority of the patients benefited on the average one point on the scale. This paper adds to the body of evidence suggesting the safety and efficacy of autologous BM-MNSCs in the treatment of MS and awaits validation through larger, randomized studies.
STUDY IN PROCESS OF PUBLISHING
MORE: https://www.ncbi.nlm.nih.gov/pubmed/27788571